From Diabetes Care to Heart Failure Management: A Potential Therapeutic Approach Combining SGLT2 Inhibitors and Plant Extracts

Overview

Journal Nutrients

Date 2022 Sep 23

PMID 36145112

Authors

Micaela Gliozzi

Roberta Macri

Anna Rita Coppoletta

Vincenzo Musolino

Cristina Carresi

Miriam Scicchitano

Francesca Bosco

Lorenza Guarnieri

Antonio Cardamone

Stefano Ruga

Federica Scarano

Saverio Nucera

Rocco Mollace

Irene Bava

Rosamaria Caminiti

Maria Serra

Jessica Maiuolo

Ernesto Palma

Vincenzo Mollace

Affiliations

Soon will be listed here.

Abstract

Diabetes is a complex chronic disease, and among the affected patients, cardiovascular disease (CVD)is the most common cause of death. Consequently, the evidence for the cardiovascular benefit of glycaemic control may reduce long-term CVD rates. Over the years, multiple pharmacological approaches aimed at controlling blood glucose levels were unable to significantly reduce diabetes-related cardiovascular events. In this view, a therapeutic strategy combining SGLT2 inhibitors and plant extracts might represent a promising solution. Indeed, countering the main cardiometabolic risk factor using plant extracts could potentiate the cardioprotective action of SGLT2 inhibitors. This review highlights the main molecular mechanisms underlying these beneficial effects that could contribute to the better management of diabetic patients.

Citing Articles

Nutritional and Nutraceutical Support to the Failing Myocardium: A Possible Way of Potentiating the Current Treatment of Heart Failure.

Macri R, Mollace R, Serra M, Scarano F, Ritorto G, Ussia S Int J Mol Sci. 2024; 25(22).

PMID: 39596298 PMC: 11594499. DOI: 10.3390/ijms252212232.

Exploring the bone marrow micro environment in thalassemia patients: potential therapeutic alternatives.

Li Z, Yao X, Zhang J, Yang J, Ni J, Wang Y Front Immunol. 2024; 15:1403458.

PMID: 39161767 PMC: 11330836. DOI: 10.3389/fimmu.2024.1403458.

Dietary Supplements in Cardiovascular and Metabolic Diseases.

Trimarco B, Santulli G Nutrients. 2024; 16(10).

PMID: 38794656 PMC: 11123989. DOI: 10.3390/nu16101418.

Plants and Their Derivatives as Promising Therapeutics for Sustainable Control of Honeybee () Pathogens.

Bava R, Castagna F, Ruga S, Nucera S, Caminiti R, Serra M Pathogens. 2023; 12(10).

PMID: 37887776 PMC: 10610010. DOI: 10.3390/pathogens12101260.

Causal associations between dried fruit intake and cardiovascular disease: A Mendelian randomization study.

Zeng Y, Cao S, Yang H Front Cardiovasc Med. 2023; 10:1080252.

PMID: 36815021 PMC: 9939508. DOI: 10.3389/fcvm.2023.1080252.

References

Cai X, Yang W, Gao X, Chen Y, Zhou L, Zhang S . The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. Obesity (Silver Spring). 2017; 26(1):70-80. DOI: 10.1002/oby.22066. View

Layton A, Vallon V, Edwards A . Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron. Am J Physiol Renal Physiol. 2016; 310(11):F1269-83. PMC: 4935777. DOI: 10.1152/ajprenal.00543.2015. View

Sukhanov S, Higashi Y, Yoshida T, Mummidi S, Aroor A, Jeffrey Russell J . The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion. Cell Signal. 2020; 77:109825. PMC: 8118186. DOI: 10.1016/j.cellsig.2020.109825. View

Zinman B, Inzucchi S, Lachin J, Wanner C, Ferrari R, Fitchett D . Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol. 2014; 13:102. PMC: 4072621. DOI: 10.1186/1475-2840-13-102. View

Sharma S, Pathak S, Gupta G, Sharma S, Singh L, Sharma R . Pharmacological evaluation of aqueous extract of syzigium cumini for its antihyperglycemic and antidyslipidemic properties in diabetic rats fed a high cholesterol diet-Role of PPARγ and PPARα. Biomed Pharmacother. 2017; 89:447-453. DOI: 10.1016/j.biopha.2017.02.048. View

Mone P, Lombardi A, Kansakar U, Varzideh F, Jankauskas S, Pansini A . Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes. J Pharmacol Exp Ther. 2022; 384(1):116-122. PMC: 9827502. DOI: 10.1124/jpet.121.001251. View

Mousum S, Ahmed S, Gawali B, Kwatra M, Ahmed A, Lahkar M . Nyctanthes arbor-tristis leaf extract ameliorates hyperlipidemia- and hyperglycemia-associated nephrotoxicity by improving anti-oxidant and anti-inflammatory status in high-fat diet-streptozotocin-induced diabetic rats. Inflammopharmacology. 2018; 26(6):1415-1428. DOI: 10.1007/s10787-018-0497-6. View

. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S83-S96. DOI: 10.2337/dc22-S006. View

Thiele K, Rau M, Hartmann N, Moller M, Mollmann J, Jankowski J . Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. ESC Heart Fail. 2022; 9(4):2233-2238. PMC: 9288802. DOI: 10.1002/ehf2.13955. View

10.

Bedi Jr K, Snyder N, Brandimarto J, Aziz M, Mesaros C, Worth A . Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure. Circulation. 2016; 133(8):706-16. PMC: 4779339. DOI: 10.1161/CIRCULATIONAHA.115.017545. View

11.

Kozics K, Klusova V, Srancikova A, Mucaji P, Slamenova D, Hunakova L . Effects of Salvia officinalis and Thymus vulgaris on oxidant-induced DNA damage and antioxidant status in HepG2 cells. Food Chem. 2013; 141(3):2198-206. DOI: 10.1016/j.foodchem.2013.04.089. View

12.

Prattichizzo F, de Candia P, Ceriello A . Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. Metabolism. 2021; 120:154799. DOI: 10.1016/j.metabol.2021.154799. View

13.

Trum M, Riechel J, Wagner S . Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na?. Int J Mol Sci. 2021; 22(15). PMC: 8347698. DOI: 10.3390/ijms22157976. View

14.

Aroor A, Das N, Carpenter A, Habibi J, Jia G, Ramirez-Perez F . Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc Diabetol. 2018; 17(1):108. PMC: 6065158. DOI: 10.1186/s12933-018-0750-8. View

15.

Schmoll D, Walker K, Alessi D, Grempler R, Burchell A, Guo S . Regulation of glucose-6-phosphatase gene expression by protein kinase Balpha and the forkhead transcription factor FKHR. Evidence for insulin response unit-dependent and -independent effects of insulin on promoter activity. J Biol Chem. 2000; 275(46):36324-33. DOI: 10.1074/jbc.M003616200. View

16.

Wilcox C, Shen W, Boulton D, Leslie B, Griffen S . Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects. J Am Heart Assoc. 2018; 7(4). PMC: 5850181. DOI: 10.1161/JAHA.117.007046. View

17.

Valdivia C, Chu W, Pu J, Foell J, Haworth R, Wolff M . Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol. 2005; 38(3):475-83. DOI: 10.1016/j.yjmcc.2004.12.012. View

18.

Shim D, Han J, Ji Y, Shin W, Koppula S, Kim M . Cichorium intybus Linn. Extract Prevents Type 2 Diabetes Through Inhibition of NLRP3 Inflammasome Activation. J Med Food. 2016; 19(3):310-7. DOI: 10.1089/jmf.2015.3556. View

19.

Wilcox C . Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors. Hypertension. 2020; 75(4):894-901. DOI: 10.1161/HYPERTENSIONAHA.119.11684. View

20.

Xu J, Hirai T, Koya D, Kitada M . Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. J Clin Med. 2022; 11(1). PMC: 8745121. DOI: 10.3390/jcm11010137. View